Susan Flick
Adult Health · Cleveland, OHNPI 1710175179
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $85,155 of the $130,844 with a category attached, or 65.1%. AstraZeneca accounts for 62.6% of it on its own, with 37 other manufacturers making up the rest. Reporting peaked in 2022 at $50,566 and has fallen 96.0% since, to $2,042 in 2025. Among adult health clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 421 payments — averaging $310.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$82K
- EMD Serono, Inc.$42K
- Astellas Pharma US Inc$2K
- Pfizer$1K
- AbbVie$734
- Rochester Medical Corporation$637
- plus $3K from 32 others
What the payments were for
- Consulting fees$1,5951%
- Speaking & faculty fees$85,15565%
- Travel & lodging$34,67927%
- Food & beverage$9,1547%
- Education$2610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 133 | $81,926 |
| EMD Serono, Inc. | 72 | $41,626 |
| Astellas Pharma US Inc | 23 | $1,787 |
| Pfizer | 18 | $1,380 |
| AbbVie | 39 | $734 |
| Rochester Medical Corporation | 20 | $637 |
| Amgen | 18 | $576 |
| Novo Nordisk | 15 | $344 |
| Lilly USA, LLC | 10 | $265 |
| Esperion Therapeutics, Inc. | 6 | $220 |
| Myovant Sciences Inc. | 5 | $176 |
| Merck | 6 | $152 |
| Exact Sciences | 5 | $95 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $89 |
| GSK | 5 | $83 |
| Lundbeck LLC | 3 | $61 |
| Sumitomo Pharma America, Inc. | 3 | $60 |
| Bausch Health US, LLC | 3 | $56 |
| Radius Health, Inc. | 3 | $55 |
| Antares Pharma, Inc. | 1 | $50 |
| Seqirus USA Inc | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $43 |
| Dexcom, Inc. | 2 | $39 |
| Eisai Inc. | 2 | $36 |
| Bayer | 2 | $35 |
| Tolmar, Inc. | 2 | $34 |
| Axsome Therapeutics, Inc. | 2 | $33 |
| Philips North America LLC | 2 | $27 |
| Coloplast | 1 | $24 |
| Foundation Medicine, Inc. | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $20 |
| Cashflow Solutions, LLC | 1 | $19 |
| Halozyme Inc | 1 | $18 |
| VBI Vaccine (delaware) Inc. | 1 | $17 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Novartis | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$130,844 in reported general payments places this provider in the 95th percentile of 1,184 adult health providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 83 | $103,197 |
| AplenzinBupropion Hbr | 11 | $62,751 |
| MyrbetriqMirabegron | 22 | $28,268 |
| FarxigaDapagliflozin Propanediol | 15 | $22,272 |
| XareltoRivaroxaban | 13 | $21,022 |
| OzempicSemaglutide | 15 | $19,527 |
| MounjaroTirzepatide | 13 | $14,730 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $7,739 |
| SynthroidLevothyroxine Sodium | 86 | $6,997 |
| Celecoxib | 53 | $5,111 |
| Dexlansoprazole DrDexlansoprazole | 13 | $4,810 |
| PaxlovidNirmatrelvir/Ritonavir | 26 | $4,288 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 25 | $4,240 |
| Hydrocortisone | 27 | $3,073 |
| Atorvastatin Calcium | 210 | $2,441 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $1,380 | $107,485109 claims |
| Bausch Health US, LLCAplenzin | $56 | $62,75111 claims |
| Astellas Pharma US IncMyrbetriq | $1,787 | $28,26822 claims |
| AstraZenecaFarxiga | $81,926 | $22,27215 claims |
| Novo NordiskOzempic | $344 | $19,52715 claims |
| Lilly USA, LLCMounjaro | $265 | $14,73013 claims |
| GSKTrelegy Ellipta | $83 | $7,73911 claims |
| AbbVieSynthroid | $734 | $6,99786 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,184 adult health providers in Ohio.
Other adult health in Cleveland
- Kathleen HarrisCleveland$28K
- Margaret TiktinCleveland$22K
- Mindy RiveraCleveland$20K
- Elizabeth CrespoCleveland$12K
- Amanda BonhamCleveland$7K
- Bonnie MohlerCanton$338K
- Andrew GuinigundoCincinnati$215K
- Gabriella McCartyWestlake$177K
- Karen SteffeyLyndhurst$145K
- Marie ChambersCenterville$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.